Kaksha Sankhe
Experience:
Academic: 3 years
Industry: NIL
Thrust research areas: Medicinal Chemistry and Analytical Chemistry
Awards:
2018: Qualified PET (PhD Entrance test)
2015: Qualified GPAT(graduate pharmacy aptitude test) http://www.gpat.in/.(AIR-1089)
2015: Qualified entrance test for National Institute of Pharmaceutical Education and Research (NIPER).http://www.niper.ac.in/(AIR 857)
Publications:
Publications: 5
Cumulativeimpact factor of Clarivate/ Thompson Reuter: 22.845
Books/Bookchapters: 1 (No. only)
GoogleScholar link: https://scholar.google.com/citations?user=b0LnWrUAAAAJ&hl=en
ORCiD link: https://orcid.org/0000-0002-3208-2608
Research/Sponsored projects:
Government: 1
Conferencesattended: 6
Workshopsattended: 4
Seminarsattended: 4
PaperPresentations: 4
Contactdetails:
E-mail: kakshavs@gmail.com
LinkedIn profile link: https://in.linkedin.com/in/kaksha-sankhe-8a8521125?original_referer=https%3A%2F%2Fwww.google.com%2F
List of publications:
Sankhe, K., Prabhu, A. and Khan, T., 2021. Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer. Chemical Biology & Drug Design, 98(1), pp.73-93. https://doi.org/10.1111/cbdd.13850
Jadhav, M., Sankhe, K., Bhandare, R.R., Edis, Z., Bloukh, S.H. and Khan, T.A., 2021. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors. Molecules, 26(17), p.5170. 10.3390/molecules26175170
Khan T, Sankhe K. DNA gyrase inhibitors. Encyclopedia of Molecular pharmacology. 2020
Sankhe K, Khan T, Trikha S, Sahu P.L. Synthesis and characterization of 6-hydroxy-3,4-dihydroquinolinone cilostazol impurity A as per Indian pharmacopeia. IJPSR. 2020.
Sankhe K, Khan T, Bhavsar C, Momin M, Omri A. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB. Expert opinion on drug delivery. 2019 May 4;16(5):525-38. https://doi.org/10.1080/17425247.2019.1609937
Khan T, Sankhe K, Suvarna V, Sherje A, Patel K, Dravyakar B. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents. Biomedicine & Pharmacotherapy. 2018 Jul 1;103: 923-38. 10.1016/j.biopha.2018.04.021